IAP4 _ BIRC5 (1_99)
- Known as:
- IAP4 _ BIRC5 (1_99)
- Catalog number:
- AM00329PU-N
- Product Quantity:
- 0.1 mg
- Category:
- -
- Supplier:
- ACR
- Gene target:
- IAP4 _ BIRC5 (1_99)
Related genes to: IAP4 _ BIRC5 (1_99)
- Gene:
- ACBD5 NIH gene
- Name:
- acyl-CoA binding domain containing 5
- Previous symbol:
- -
- Synonyms:
- DKFZp434A2417, KIAA1996
- Chromosome:
- 10p12.1
- Locus Type:
- gene with protein product
- Date approved:
- 2003-11-11
- Date modifiied:
- 2014-11-19
- Gene:
- AK9 NIH gene
- Name:
- adenylate kinase 9
- Previous symbol:
- C6orf224, AKD2, C6orf199, AKD1
- Synonyms:
- FLJ42177, FLJ25791, dJ70A9.1, MGC26954
- Chromosome:
- 6q21
- Locus Type:
- gene with protein product
- Date approved:
- 2009-03-13
- Date modifiied:
- 2015-10-15
- Gene:
- ASAP3 NIH gene
- Name:
- ArfGAP with SH3 domain, ankyrin repeat and PH domain 3
- Previous symbol:
- DDEFL1
- Synonyms:
- FLJ20199, UPLC1, CENTB6
- Chromosome:
- 1p36.12
- Locus Type:
- gene with protein product
- Date approved:
- 2001-03-27
- Date modifiied:
- 2016-10-05
- Gene:
- BIRC5 NIH gene
- Name:
- baculoviral IAP repeat containing 5
- Previous symbol:
- API4
- Synonyms:
- EPR-1, survivin
- Chromosome:
- 17q25.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-06-10
- Date modifiied:
- 2016-10-04
- Gene:
- CCR9 NIH gene
- Name:
- C-C motif chemokine receptor 9
- Previous symbol:
- GPR28
- Synonyms:
- GPR-9-6, CDw199
- Chromosome:
- 3p21.31
- Locus Type:
- gene with protein product
- Date approved:
- 1999-09-17
- Date modifiied:
- 2016-03-14
Related products to: IAP4 _ BIRC5 (1_99)
Related articles to: IAP4 _ BIRC5 (1_99)
- Glioma represents the most prevalent and lethal primary malignant tumor of the central nervous system, characterized by remarkable cellular heterogeneity and poor prognosis. Comprehensive characterization of glioma at single-cell resolution is essential for identifying novel therapeutic targets and improving patient outcomes. - Source: PubMed
Publication date: 2026/05/28
Gu ChengcongWu XiaojinYang Liang - Synthetic polyinosinic:polycytidylic acid (poly(I:C)) offers an attractive cancer therapeutic by operating on two fronts at once, combining direct tumor cell killing with immunostimulatory activity. Yet, these dual functions can only be efficiently harnessed when intracellular delivery is sufficiently effective to enable poly(I:C) to reach and activate its intracellular receptors. We addressed this delivery challenge by developing pH-responsive formulations using lipoamino fatty acid xenopeptide (LAF-XP) carriers, composed of polar cationizable succinoyl tetraethylene pentamine (Stp) and apolar cationizable LAF building blocks in defined architectures. In particular, poly(I:C)-lipid nanoparticles (LNPs) formulated with bundle LAF-Stp XP carriers displayed increased anti-tumoral activity at decreased dosage across multiple cancer cell models, compared to control formulations. In parallel, LAF-XP LNP-delivered poly(I:C) activated immune responses, including CXCL10 production by tumor cells, and activation of peripheral blood mononuclear cells (PBMCs), characterized by increased phenotypic markers (CD69 and LAMP-1/CD107a) and functional molecules (e.g., IFN-γ and granzyme B). Conditioned supernatant of pre-stimulated PBMCs with poly(I:C) reduced cancer cell viability, highlighting the contribution of PBMC-released factors to cancer cell death. Of particular novelty is the combination of poly(I:C) with siRNA-mediated survivin knockdown to increase apoptosis in cancer cells using the bundle LAF-XP LNP. Collectively, our findings establish efficient LAF-XP LNPs as a versatile platform that supports multi-layered therapeutic strategies. - Source: PubMed
Publication date: 2026/05/30
Yazdi MinaHasheminejad ZahraHachani KhouloudKache JoyceGrau MelinaWollenberg BarbaraBashiri Dezfouli AliWagner Ernst - Cisplatin (Cis) resistance and dose-limiting toxicity remain major challenges in the treatment of cervical cancer, necessitating the development of more effective combination strategies. The effects of gallic acid (GA), alone and in combination with Cis, were evaluated in HeLa cervical cancer cells using cell viability, apoptosis, gene expression, caspase activity, and cytokine profiling assays. Drug interactions were assessed using the Chou-Talalay method. The GA+Cis combination was associated with enhanced cytotoxicity compared to single-agent treatments, with combination index (CI) values ranging from 0.61 to 0.92, indicating synergistic interactions. Selectivity index (SI) values exceeding 2 at 48 h suggested preferential cytotoxicity toward cancer cells. The combination treatment significantly increased apoptotic cell populations and was accompanied by elevated caspase-3 and caspase-9 activities. Gene expression analysis revealed increased BAX and CASP3 levels, along with decreased BCL2 and BIRC5 expression, resulting in an increased BAX/BCL2 ratio. In addition, cell cycle analysis indicated accumulation in the G2/M phase, while cytokine profiling demonstrated reduced levels of pro-inflammatory cytokines and increased IL-10 levels under combination treatment conditions. These findings suggest that GA enhances the biological activity of Cis in cervical cancer cells through coordinated modulation of apoptosis, cell cycle dynamics, and inflammatory signaling. However, these results are based on in vitro observations, and further in vivo and mechanistic studies are required to confirm the therapeutic potential of this combination strategy. - Source: PubMed
Publication date: 2026/05/23
Ozan ElifTuncer Mehmet CudiÖzdemir İlhan - Retinoblastoma is the most common pediatric intraocular malignancy, although it remains a rare disease overall, yet the molecular targets and therapeutic vulnerabilities sustaining its most aggressive proliferative cell states remain incompletely defined. We aimed to identify actionable molecular regulators and potential therapeutic targets of malignant retinoblastoma progression using integrated single-cell transcriptomics and functional validation. - Source: PubMed
Publication date: 2026/05/21
Chen YingtongLi XiaohanZhong FuhuaWang XiaoyaWang QiangCao DiDong ShaoweiZhang ChengyueSong HuibinLin Chen - The integration of molecular computation with nanomedicine holds transformative potential for precision cancer theranostics. However, achieving an intelligent, multi-input decision-making process within living cells remains a formidable challenge because of the complexity of intracellular signaling networks. Here, we present a set of DNA tetrahedron logic processors that enable smart intracellular computing through a programmable three-input architecture capable of executing seven Boolean operations-OR, AND, NOR, NAND, XOR, majority (MAJ), and OR-AND-in response to endogenous miRNA signals. Building upon the cell-internalizable tetrahedral framework nucleic acid, this processor functions as an autonomous sense-and-treat module: it decodes combinatorial biomarker states and conditionally releases therapeutic siRNA only when a predefined logical condition is met. As a proof of concept, in precision oncology, we engineered a MAJ-gated nanoplatform (siR@MAJ) that selectively silences survivin in MCF-7 breast cancer cells that exhibit a specific tri-miRNA signature while sparing other cell types. This approach has achieved potent tumor suppression both in vitro and in vivo with high specificity and minimal off-target effects. By integrating multi-target detection into a single logic circuit, this processor significantly improves the discriminative capability within complex biological environments. Our work establishes a foundational platform for intelligent intracellular diagnostics and therapy, paving the way toward adaptive, logic-driven nanomedicine. - Source: PubMed
Publication date: 2026/06/02
Gao YangWang YunQin YunlongZhang GeruGao ShaojingyaChen WenYang SiyiYang XiaoTang YuanlinHe YaoLin YunfengWillner ItamarTian TaoranCai Xiaoxiao